AstraZeneca’s triplet with Imfinzi, treme and chemo works on a key endpoint for frontline lung cancer
AstraZeneca’s big comeback year just got better.
After disappointing investors with repeated setbacks on their PD-L1/CTLA-4 matchup of Imfinzi and tremelimumab, the pharma giant said Monday that the combo — combined with a choice of chemotherapies — worked in delaying disease progression in frontline cases of Stage 4 non-small cell lung cancer, hitting a key endpoint in the closely-watched POSEIDON study. And on the primary, Imfinzi and chemo together also hit on the progression-free survival yardstick.
Researchers also said that the triple approach came out with a similar safety profile to chemo alone, a big added benefit for patients.
We don’t have the hard data yet, but a solid success here would put AstraZeneca within reach of challenging Merck’s Keytruda and Bristol-Myers Squibb’s Opdivo in one of the most lucrative sectors in the cancer drug market. Overall survival data — which is critical — are expected to follow next year, as AstraZeneca continues to pursue a bigger share of the market with a slate of late-stage studies. That lineup includes PEARL, which is testing Imfinzi as a monotherapy in NSCLC.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 67,600+ biopharma pros reading Endpoints daily — and it's free.